ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DMTX Dimension Therapeutics, Inc.

5.95
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Dimension Therapeutics, Inc. NASDAQ:DMTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.95 5.95 6.00 0 01:00:00

Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences

24/08/2016 1:00pm

GlobeNewswire Inc.


DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more DIMENSION THERAPEUTICS, INC. Charts.

Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will participate in two upcoming investor conferences:

  • Citi's 11th Annual Biotech ConferencePanel: Gene Therapy: A New EraWednesday, September 7, 2016 at 1:00 p.m. Eastern TimeThe Mandarin Oriental Hotel, Boston, MA
  • 2016 Wells Fargo Healthcare ConferenceFireside Chat: Thursday, September 8, 2016 at 3:30 p.m. Eastern TimeThe Westin Boston Waterfront Hotel, Boston, MA

Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.dimensiontx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Dimension Therapeutics

Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.

For more information, please visit http://www.dimensiontx.com.

CONTACT:

Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com

Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com

1 Year DIMENSION THERAPEUTICS, INC. Chart

1 Year DIMENSION THERAPEUTICS, INC. Chart

1 Month DIMENSION THERAPEUTICS, INC. Chart

1 Month DIMENSION THERAPEUTICS, INC. Chart

Your Recent History

Delayed Upgrade Clock